Merck Partners with China’s BGI on Genomics

Merck, known as MSD outside North America, has formally launched a collaboration with BGI, the Shenzhen-based genomics powerhouse. The two companies will seek to discover and develop biomarkers as a means toward drug discovery, drug development and diagnostics applications. In September 2010, the two entities signed an agreement to explore ways to work together, and this partnership is the result. More details.... Stock Symbol: (NYSE: MRK)     Share this with colleagues: